| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8440838 | European Journal of Cancer | 2016 | 6 Pages |
Abstract
We demonstrate in ACC patients that PF, as assessed by patients using the EORTC QLQ-C30, is superior in terms of prognostic value to WHO PS as scored by physicians. Our data support to include the results of baseline EORTC QLQ-C30 PF instead of WHO PS as a stratification parameter in oncology trials.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
L. Mol, P.B. Ottevanger, M. Koopman, C.J.A. Punt,